Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | TKT | P29401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27905191 | 0.83 | LMNA (0.39) | LMNACYP1A2TSHRKDM4EPDK2 | |
| SCHEMBL27461909 | 0.80 | KDM4E (0.31) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12186160 | 0.79 | LMNA (0.42) | LMNACYP1A2TSHRKDM4EPDK2 | |
| SCHEMBL20310245 | 0.78 | LMNA (0.61) | LMNACYP1A2TSHRKDM4EALDH1A1 | |
| SCHEMBL30565606 | 0.78 | LMNA (0.61) | LMNACYP1A2TSHRKDM4EALDH1A1 | |
| SCHEMBL13167669 | 0.78 | LMNA (0.43) | LMNACYP1A2TSHRKDM4EALDH1A1 | |
| SCHEMBL11325842 | 0.77 | LMNA (0.41) | LMNACYP1A2TSHRKDM4EPDK2 | |
| SCHEMBL14677401 | 0.77 | LMNA (0.46) | LMNACYP1A2TSHRKDM4EALDH1A1 | |
| SCHEMBL2120597 | 0.77 | KDM4E (0.48) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Bromide SCHEMBL20679766 | 0.77 | LMNA (0.59) | LMNACYP1A2TSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-4154844-A | ANTIHISTAMINE, GASTRIC JUICE ANTISECRETORY AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
| US-4151288-A | ANTHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-04-24 | — | — | US | disclosed |
| US-4137237-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4137234-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4070475-A | THIOALKYL-, AMINOALKYL-, AND OXYALKYL- SUBSTITUTED GUANIDINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-24 | — | — | US | disclosed |
| US-4024271-A | INHIBITORS OF HISTAMINE ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-17 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-4018931-A | INHIBITION OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |
| US-3950333-A | HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
| US-3950353-A | HISTAMINE INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | LMNA 3446/4885CYP1A2 697/4885TSHR 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.